List of Tables
Table 1. Global Anti-VEGF Ophthalmic Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-VEGF Ophthalmic Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-VEGF Ophthalmic Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-VEGF Ophthalmic Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Anti-VEGF Ophthalmic Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Anti-VEGF Ophthalmic Drug Sales by Region (2020-2025) & (K Units)
Table 8. Global Anti-VEGF Ophthalmic Drug Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Anti-VEGF Ophthalmic Drug Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Anti-VEGF Ophthalmic Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global Anti-VEGF Ophthalmic Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Anti-VEGF Ophthalmic Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Ophthalmic Drug as of 2024)
Table 16. Global Anti-VEGF Ophthalmic Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Anti-VEGF Ophthalmic Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Anti-VEGF Ophthalmic Drug Manufacturing Base and Headquarters
Table 19. Global Anti-VEGF Ophthalmic Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Anti-VEGF Ophthalmic Drug Sales by Type (2020-2025) & (K Units)
Table 23. Global Anti-VEGF Ophthalmic Drug Sales by Type (2026-2031) & (K Units)
Table 24. Global Anti-VEGF Ophthalmic Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Anti-VEGF Ophthalmic Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Anti-VEGF Ophthalmic Drug ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Anti-VEGF Ophthalmic Drug Sales by Application (2020-2025) & (K Units)
Table 29. Global Anti-VEGF Ophthalmic Drug Sales by Application (2026-2031) & (K Units)
Table 30. Anti-VEGF Ophthalmic Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Anti-VEGF Ophthalmic Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Anti-VEGF Ophthalmic Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Anti-VEGF Ophthalmic Drug ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Anti-VEGF Ophthalmic Drug Growth Accelerators and Market Barriers
Table 37. North America Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Anti-VEGF Ophthalmic Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Anti-VEGF Ophthalmic Drug Growth Accelerators and Market Barriers
Table 40. Europe Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Anti-VEGF Ophthalmic Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Anti-VEGF Ophthalmic Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Anti-VEGF Ophthalmic Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Anti-VEGF Ophthalmic Drug Investment Opportunities and Key Challenges
Table 47. Central and South America Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Anti-VEGF Ophthalmic Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Eyetech Corporation Information
Table 51. Eyetech Description and Major Businesses
Table 52. Eyetech Product Models, Descriptions and Specifications
Table 53. Eyetech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Eyetech Sales Value Proportion by Product in 2024
Table 55. Eyetech Sales Value Proportion by Application in 2024
Table 56. Eyetech Sales Value Proportion by Geographic Area in 2024
Table 57. Eyetech Anti-VEGF Ophthalmic Drug SWOT Analysis
Table 58. Eyetech Recent Developments
Table 59. Pfizer Inc Corporation Information
Table 60. Pfizer Inc Description and Major Businesses
Table 61. Pfizer Inc Product Models, Descriptions and Specifications
Table 62. Pfizer Inc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Pfizer Inc Sales Value Proportion by Product in 2024
Table 64. Pfizer Inc Sales Value Proportion by Application in 2024
Table 65. Pfizer Inc Sales Value Proportion by Geographic Area in 2024
Table 66. Pfizer Inc Anti-VEGF Ophthalmic Drug SWOT Analysis
Table 67. Pfizer Inc Recent Developments
Table 68. Roche Corporation Information
Table 69. Roche Description and Major Businesses
Table 70. Roche Product Models, Descriptions and Specifications
Table 71. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Roche Sales Value Proportion by Product in 2024
Table 73. Roche Sales Value Proportion by Application in 2024
Table 74. Roche Sales Value Proportion by Geographic Area in 2024
Table 75. Roche Anti-VEGF Ophthalmic Drug SWOT Analysis
Table 76. Roche Recent Developments
Table 77. Novartis Corporation Information
Table 78. Novartis Description and Major Businesses
Table 79. Novartis Product Models, Descriptions and Specifications
Table 80. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Novartis Sales Value Proportion by Product in 2024
Table 82. Novartis Sales Value Proportion by Application in 2024
Table 83. Novartis Sales Value Proportion by Geographic Area in 2024
Table 84. Novartis Anti-VEGF Ophthalmic Drug SWOT Analysis
Table 85. Novartis Recent Developments
Table 86. Regeneron Corporation Information
Table 87. Regeneron Description and Major Businesses
Table 88. Regeneron Product Models, Descriptions and Specifications
Table 89. Regeneron Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Regeneron Sales Value Proportion by Product in 2024
Table 91. Regeneron Sales Value Proportion by Application in 2024
Table 92. Regeneron Sales Value Proportion by Geographic Area in 2024
Table 93. Regeneron Anti-VEGF Ophthalmic Drug SWOT Analysis
Table 94. Regeneron Recent Developments
Table 95. Bayer Corporation Information
Table 96. Bayer Description and Major Businesses
Table 97. Bayer Product Models, Descriptions and Specifications
Table 98. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Bayer Recent Developments
Table 100. Regeneron Pharmaceuticals Corporation Information
Table 101. Regeneron Pharmaceuticals Description and Major Businesses
Table 102. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 103. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Regeneron Pharmaceuticals Recent Developments
Table 105. Genentech Corporation Information
Table 106. Genentech Description and Major Businesses
Table 107. Genentech Product Models, Descriptions and Specifications
Table 108. Genentech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Genentech Recent Developments
Table 110. Samsung Bioepis Corporation Information
Table 111. Samsung Bioepis Description and Major Businesses
Table 112. Samsung Bioepis Product Models, Descriptions and Specifications
Table 113. Samsung Bioepis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Samsung Bioepis Recent Developments
Table 115. Biogen Corporation Information
Table 116. Biogen Description and Major Businesses
Table 117. Biogen Product Models, Descriptions and Specifications
Table 118. Biogen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Biogen Recent Developments
Table 120. Qilu Pharmaceutical Corporation Information
Table 121. Qilu Pharmaceutical Description and Major Businesses
Table 122. Qilu Pharmaceutical Product Models, Descriptions and Specifications
Table 123. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Qilu Pharmaceutical Recent Developments
Table 125. Innovent Biologics Corporation Information
Table 126. Innovent Biologics Description and Major Businesses
Table 127. Innovent Biologics Product Models, Descriptions and Specifications
Table 128. Innovent Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Innovent Biologics Recent Developments
Table 130. Kanghong Pharmaceutical Corporation Information
Table 131. Kanghong Pharmaceutical Description and Major Businesses
Table 132. Kanghong Pharmaceutical Product Models, Descriptions and Specifications
Table 133. Kanghong Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Kanghong Pharmaceutical Recent Developments
Table 135. Taikang Biology Corporation Information
Table 136. Taikang Biology Description and Major Businesses
Table 137. Taikang Biology Product Models, Descriptions and Specifications
Table 138. Taikang Biology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Taikang Biology Recent Developments
Table 140. Key Raw Materials Distribution
Table 141. Raw Materials Key Suppliers
Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 143. Milestones in Production Technology Evolution
Table 144. Distributors List
Table 145. Market Trends and Market Evolution
Table 146. Market Drivers and Opportunities
Table 147. Market Challenges, Risks, and Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGF Ophthalmic Drug Product Picture
Figure 2. Global Anti-VEGF Ophthalmic Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Pegaptanib Product Picture
Figure 4. Ranibizumab Product Picture
Figure 5. Aflibercept Product Picture
Figure 6. Brolucizumab Product Picture
Figure 7. Faricimab Product Picture
Figure 8. Global Anti-VEGF Ophthalmic Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Online Sales
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Retail Pharmacy
Figure 13. Others
Figure 14. Anti-VEGF Ophthalmic Drug Report Years Considered
Figure 15. Global Anti-VEGF Ophthalmic Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 17. Global Anti-VEGF Ophthalmic Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Region (2020-2031)
Figure 19. Global Anti-VEGF Ophthalmic Drug Sales (2020-2031) & (K Units)
Figure 20. Global Anti-VEGF Ophthalmic Drug Sales (CAGR) by Region (2020-2031) (K Units)
Figure 21. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Region (2020-2031)
Figure 22. Top 5 and Top 10 Manufacturers Anti-VEGF Ophthalmic Drug Sales Volume Market Share in 2024
Figure 23. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Ranking (2024)
Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 25. Pegaptanib Revenue Market Share by Manufacturer in 2024
Figure 26. Ranibizumab Revenue Market Share by Manufacturer in 2024
Figure 27. Aflibercept Revenue Market Share by Manufacturer in 2024
Figure 28. Brolucizumab Revenue Market Share by Manufacturer in 2024
Figure 29. Faricimab Revenue Market Share by Manufacturer in 2024
Figure 30. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2020-2031)
Figure 31. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2020-2031)
Figure 32. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2020-2031)
Figure 33. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application (2020-2031)
Figure 34. North America Anti-VEGF Ophthalmic Drug Sales YoY (2020-2031) & (K Units)
Figure 35. North America Anti-VEGF Ophthalmic Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) in 2024
Figure 37. North America Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Anti-VEGF Ophthalmic Drug Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Anti-VEGF Ophthalmic Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) in 2024
Figure 47. Europe Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 52. France Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Anti-VEGF Ophthalmic Drug Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Anti-VEGF Ophthalmic Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 67. India Anti-VEGF Ophthalmic Drug Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Anti-VEGF Ophthalmic Drug Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Anti-VEGF Ophthalmic Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Anti-VEGF Ophthalmic Drug Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Anti-VEGF Ophthalmic Drug Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Anti-VEGF Ophthalmic Drug Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Anti-VEGF Ophthalmic Drug Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Anti-VEGF Ophthalmic Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Anti-VEGF Ophthalmic Drug Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Anti-VEGF Ophthalmic Drug Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Anti-VEGF Ophthalmic Drug Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Anti-VEGF Ophthalmic Drug Revenue (2020-2025) & (US$ Million)
Figure 88. Anti-VEGF Ophthalmic Drug Industry Chain Mapping
Figure 89. Regional Anti-VEGF Ophthalmic Drug Manufacturing Base Distribution (%)
Figure 90. Global Anti-VEGF Ophthalmic Drug Production Market Share by Region (2020-2031)
Figure 91. Anti-VEGF Ophthalmic Drug Production Process
Figure 92. Regional Anti-VEGF Ophthalmic Drug Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
